• Human APIs PowderRespiratory Drugs Raw Material Antiviral Antibacterial Antipyretic Analgesics Antihistamine Drugs Antineoplastic Cosmetic Raw Material
  • Pharmaceutical IntermediatesPharmaceutical intermediates Nutritional Supplements Pharmaceutical raw materials
  • OEM & ODMCapsule Softgel Capsule Gummies Drop & drinks Tables
  • Veterinary raw materialsAntibacterial anti-inflammatory Respiratory Drugs Anthelmintics Antiviral drugs Feed additives
  • About UsCompany profileQualificationQuality AssuranceService teamFactory TourR&D Center
  • Pentoxifylline CAS 6493-05-6 Raw Materials Powder

    • Pentoxifylline CAS 6493-05-6 Raw Materials Powder
    • Pentoxifylline CAS 6493-05-6 Raw Materials Powder
    • Pentoxifylline CAS 6493-05-6 Raw Materials Powder storehouse
    • Pentoxifylline CAS 6493-05-6 Raw Materials Powder quality testing
    • Pentoxifylline CAS 6493-05-6 Raw Materials Powder quality testing
    • Pentoxifylline CAS 6493-05-6 Raw Materials Powder certificate

    Product Overview:

    Pentoxifylline Powder (BL-191) is a blood rheology modifier.Pentoxifylline CAS 6493-05-6 is an orally active, non-selective phosphodiesterase (PDE) inhibitor with immunomodulatory, anti-inflammatory, hemodynamic, anti-fibrinolytic and anti-proliferative effects. Pentoxifylline Raw Materials can be used to study peripheral vascular disease, cerebrovascular disease, and several other diseases involving local microcirculatory defects.

    Pentoxifylline CAS 6493-05-6 Raw Materials Powder Attributes

    Name: Pentoxifylline CAS 6493-05-6 Raw Materials Powder

    CAS: 6493-05-6

    MF: C13H18N4O3

    Pentoxifylline Powder

    MW: 278.31

    EINECS: 229-374-5

    Specification​: 99% min Pentoxifylline 

    Sample: Pentoxifylline Powder

    Brand: Henrikang

    Appearance: White Powder

    Storage: Cool Dry Place

    Shelf Life: 2 Years

    Test Method: HPLC

    Portal:https://henrikang.en.made-in-china.com/

    Pentoxifylline CAS 6493-05-6 Raw Materials Powder Details

    Pentoxifylline Powder Usage and Synthesis.

    Pentoxifylline Powder (BL-191) is a blood rheology modifier. Pentoxifylline CAS 6493-05-6 is an orally active, non-selective phosphodiesterase (PDE) inhibitor with immunomodulatory, anti-inflammatory, hemodynamic, anti-fibrinolytic and anti-proliferative effects. Pentoxifylline CAS 6493-05-6 is an orally active, non-selective phosphodiesterase (PDE) inhibitor with immunomodulatory, anti-inflammatory, hemodynamic, anti-fibrinolytic and anti-proliferative effects.

    Pentoxifylline Powder


    Materials can be used to study peripheral vascular disease, cerebrovascular disease, and several other diseases involving local microcirculatory defects. Pentoxifylline Raw Materials can be used to study peripheral vascular disease, cerebrovascular disease, and several other diseases involving local microcirculatory defects.

    Pentoxifylline Powder Factory


    Pentoxifylline , commonly used dosage forms include enteric-coated tablets, sustained release tablets, injections. It's a vasodilator. It can be used to improve cerebral circulation after ischemic stroke, and can be used in the treatment of peripheral vascular diseases, such as chronic obliterans with intermittent claudication.

    Application/Function of Pentoxifylline Powder.

    Hexaconitine Enteric Tablets/ Hexaconitine Extended Release Tablets:

    It is used to improve cerebral circulation after ischemic stroke and for the treatment of peripheral vascular diseases such as chronic occlusive vasculitis with intermittent claudication.

    Hexanone cacodyline injection/hexanone cacodyline for injection/hexanone cacodyline sodium chloride injection/hexanone cacodyline glucose injection:

    Pentoxifylline Powder

    • 1, cerebral blood circulation disorders such as temporary cerebral ischemic attack, post-stroke, cerebral ischemia-induced brain dysfunction.
    • 2, peripheral blood circulation disorders such as chronic embolic vasculitis, etc.
    • 3, inner ear circulation disorders such as sudden deafness, senile tinnitus and deafness.
    • 4、Ocular circulation disorders such as diabetic retinal artery embolism.

    Pharmacological effects of Pentoxifylline Powder

    Hexaconitine Enteric Tablets / Hexaconitine Extended Release Tablets:

    This product is a nonspecific peripheral vasodilator that diastens isolated canine basilar arteries. Intravenous injection increases blood volume in the canine brain, reduces cerebral vascular resistance, and promotes oxygen and glucose metabolism in the brain. It can enhance the deformability of rat red blood cells, reduce blood viscosity and increase capillary flow. Oral administration can inhibit laser-induced mesenteric artery thrombosis in rats.

    Hexanone cacodylate injection:

    The exact mode of action of hexoketococine and its metabolites by reducing blood viscosity and altering blood rheology and leading to improvement in clinical symptoms has yet to be determined.
    Hexaconitine has a dose-dependent reduction in blood viscosity, increases the deformability of red blood cells, improves the blood rheological properties of leukocytes, and inhibits the adhesion and activation of neutrophils. In patients with chronic peripheral arterial disease, it increases blood flow, affects microcirculation and improves tissue oxygenation.

    Hexaconitine for Injection:

    It improves blood circulation in the brain and extremities, increases blood flow in arteries and capillaries and reduces peripheral vascular resistance, but has no effect on blood pressure.

    It also improves the rheological properties of blood by improving the deformability of pathologically damaged red blood cells, inhibiting platelet aggregation, and reducing blood viscosity, thereby increasing the nutritive microcirculation in the ischemic local area. It also improves the oxidative capacity of hypoxic tissues and has a diastolic effect on bronchial tubes.

    Hexanone cacodyline sodium chloride injection/hexanone cacodyline glucose injection:

    Hexanone cacotheline and its metabolites improve blood rheology by reducing blood viscosity; the exact mode of action and the effect leading to improvement in clinical symptoms has yet to be determined. Hexaconitine has a dose-dependent effect on reducing blood viscosity, increasing red blood cell deformability, improving blood rheological properties of leukocytes, and inhibiting neutrophil adhesion and activation. In patients with chronic peripheral arterial vascular disease, it increases blood flow, affects microcirculation and improves tissue oxygenation.

    Characterization of Pentoxifylline Powder

    • (1) Enteric-coated tablets: enteric-coated tablets, appearing white after removing the coating.
    • (2) Hexaconitine extended-release tablets: film-coated tablets, appearing white or off-white after removing the film coating.
    • (3) Hexaconitine injection: colorless clear liquid.
    • (4) Hexaconitine for injection: white or off-white loose mass or powder.
    • (5) Hexaconitine sodium chloride injection: colorless clear liquid.
    • (6) Hexaconitine glucose injection: colorless clear liquid.

    Specification of Pentoxifylline

    • (1) Hexaconitine enteric tablets: 0.1g.
    • (2) Hexaconitine extended-release tablets: 0.4g.
    • (3) Hexaconitine injection: 2ml: 0.1g; 5ml: 0.1g.
    • (4) Hexaconitine for injection: 0.1g.
    • (5) Hexaconitine sodium chloride injection: 100ml: 0.1g of hexaconitine and 0.9g of sodium chloride.
    • (6) Hexanone cocaine glucose injection: 250ml: 0.1g of hexanone cocaine and 12.5g of glucose.
    Our advantage
    Our Factory
    Shipping
    Tel: 86-29-89601602
    WhatsApp: 8615091775531
    WeChat: 15091775531
    E-mail: sales21@interlgroup.com
    Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
    ©2023 Xi'an Henrikang Biotech Co., Ltd.,